More people with non-small cell lung cancer (NSCLC) are likely to benefit from new drugs that target molecular alterations in tumour cells, with less need for chemotherapy, following results of multiple landmark clinical trials reported for the first time in late-breaking presentations at the ESMO Congress 2023 (1-7).
Abcam agrees to $5.7B sale to Danaher amid founder’s push for a board seat
Danaher will buy Abcam, a research tools supplier relied upon by many biopharmas, for an enterprise value of about $5.7 billion, the companies announced Monday
August 29, 2023